Martire, S., Suryawwanshi, V., Wang, X., et al. Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

VIEW POSTER

Onboard, membrane-tethered IL-12 boosts potency and maintains selectivity of a Tmod NOT gate

Imboden, S., Lee, R., Zampieri, A., et al. Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

VIEW POSTER

EVEREST‑1: Initial safety data from a seamless phase 1/2 study of A2B530, a logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA‑LOH

Grierson, P., Punekar, S., Hazim, A., et al. Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

VIEW POSTER

Signal 1 boosters for Tmod: addressing the next obstacle in cell therapy for solid tumors

Radecki, K., Oh, J., Kirsh, C., et al. Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

VIEW POSTER

EVEREST‑2: A seamless phase 1 / 2 study of A2B694, a logic‑gated Tmod CAR T‑cell therapy, in patients with mesothelin‑expressing solid tumors with human leukocyte antigen‑A*02 loss of heterozygosity

Molina, J., Hazim, A., Dorigo, O., et al. Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

VIEW POSTER

Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)

Smith CJ, Simeone DM, Grierson PM, et al. Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

VIEW POSTER

EVEREST‑1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

Molina JR, Simeone DM, Smith CJ, et al. Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

VIEW POSTER

EVEREST‑2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

Punekar SR, Hecht JR, Smith CJ, et al. Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

VIEW POSTER

Defining The Biophysical Design Parameters For Logic-Gated CAR-T Systems

Partin AC, Bruno R, Shafaattalab S, et al. Poster presentation for the 2024 PEGS Conference. May 2024.

VIEW POSTER

BASECAMP‑1: A Master Prescreening Study to Identify Patients with High‑risk or Metastatic Solid Tumors with HLA Loss of Heterozygosity in Preparation for Tmod™ CAR T‑cell Therapy Trials

Simeone DM, Hecht JR, Smith C, et al. Poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2023.

VIEW POSTER

EVEREST-1: A Seamless Phase 1/2 Study of CEA-directed Logic-gated Tmod™ CAR T-cell Therapy (A2B530) in Adults with Solid Tumors Associated with CEA Expression Also Exhibiting HLA Loss of Heterozygosity (LOH)

Punekar SR, Welling T, Hecht JR, et al. Poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2023.

VIEW POSTER

BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors to Identify Patients for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated Tmod Chimeric Antigen Receptor (CAR) T-Cell Therapy

Smith CJ, Lau S, Garon E, et al. Poster presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 Targeted Therapies of Lung Cancer Meeting. February 2023.

VIEW POSTER

BASECAMP-1: Leveraging HLA-A Loss of Heterozygosity in Solid Tumors by NGS to Identify Patients with Relapsed Solid Tumors for Future CEA and MSLN Logic-gated Tmod CAR T-cell Therapy.

Simeone DM, Morelli MP, Hecht JR, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER

An NGS Assay to Identify HLA-A Loss of Heterozygosity for Future CEA and MSLN Logic-gated CAR-T Solid Tumor Protocols Designed for Reduced On-target, Off-tumor Toxicity

Kopetz S, Morelli MP, Molina J, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER

A2B530, An Autologous CEA-directed Tmod T-cell therapy with An Inhibitory Receptor Gated by HLA-A*02 to Target Colorectal, Pancreatic, and Lung Cancer

Hecht, JR Sandberg ML, Wang X, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER

A2B694, An Autologous Logic-gated Cell Therapy Targeting Mesothelin

Molina J, Tokatlian T, Wang J, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER

A Powerful, Precise Targeting System Controlled by Tumor Deletions Transforms CEA and MSLN CAR-T Cells Into Tumor-Selective Agents

Hamburger A, Xu H, Ando Y, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J, Go W, Kopetz S, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

Warshaviak D, Nampe D, Wang X, et al. Poster presentation at The Essential Protein Engineering & Cell Therapy Summit Virtual. August 2020.

VIEW POSTER

Dr Hecht on the Investigation of A2B530 in Germline HLA-A*02 Heterozygous Solid Tumors

Hecht J. R. Interview conducted on OncLive. May 2023.

VIEW INTERVIEW

Dr Simeone on the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

Simeone D. Interview conducted on OncLive. April 2023.

VIEW INTERVIEW

Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells

Tokatlian T. Presentation at the JAX Journal Club. November 2022.

VIEW PRESENTATION

Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells

DiAndreth A. Interview conducted at Onco Cell Therapy Summit (OCTS) USA 2022. June 2022.

VIEW INTERVIEW

The Future of Logic-gated Cell Therapy

Go W. Interview conducted at the 4th International Workshop on CAR-T (iwCAR-T 2022). April 2022.

VIEW INTERVIEW

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

Tmod™ T cell Therapy Platform Overview

Kamb, A. Interviews conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J. Oral poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW PRESENTATION

Managing Clinical Safety and Toxicity for Improved Patient Outcomes

Go W. Oral presentation at CAR-TCR Summit 2021. August 2021.

VIEW PRESENTATION

Optimizing Efficiency in Trial Sponsor and Clinician Relationships

Geiger B, Matthews A, Melvin P, et al. Panel discussion at CAR-TCR Summit 2021. August 2021.

VIEW PRESENTATION

Next-generation Logic-gated Cell Therapy

Go W. Oral presentation at the International Workshop on CAR-T 2021. April 2021.

VIEW PRESENTATION

Engineered T Cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Oral presentation at 3rd Cell Therapies and Immunotherapy Conference. October 2020.

VIEW PRESENTATION

Explore Our Pipeline

A2 BIOTHERAPEUTICS, Reg. U.S. Pat. & Tm. Off.